In spin­ning out can­cer pipeline, Alk­er­mes cites In­fla­tion Re­duc­tion Ac­t's hy­po­thet­i­cal in­cen­tives for bi­o­log­ics R&D

Alk­er­mes an­nounced Wednes­day morn­ing it would siphon off its bur­geon­ing on­col­o­gy busi­ness, and cit­ed one of Pres­i­dent Joe Biden’s sig­na­ture pieces of leg­is­la­tion as a mo­ti­va­tor.

The Irish biotech de­cid­ed to spin out its can­cer pipeline in or­der to cap­i­tal­ize on bi­o­log­ics re­search, ex­ecs said Wednes­day, fol­low­ing Biden’s sign­ing of the In­fla­tion Re­duc­tion Act in­to law. With the com­ments, Alk­er­mes be­came the third bio­phar­ma com­pa­ny in the last week to cite the IRA in its busi­ness and R&D de­ci­sions, fol­low­ing Al­ny­lam and Eli Lil­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER